Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04184115 · ClinicalTrials.gov registry record · Phase 3
Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness
A Phase 3 study, sponsored by Repurposed Therapeutics.
- Completed
- Registry status
- Phase 3
- Development phase
- 102
- Enrollment target
NCT04184115: Completed Phase 3 study, sponsored by Repurposed Therapeutics.
NCT04184115 is a Phase 3 study that has completed, run by Repurposed Therapeutics. The registered enrollment target is 102 participants, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04184115, a Phase 3 study, has completed, sponsored by Repurposed Therapeutics.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 102 participants
- Enrollment target
Study Summary
Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of nausea associated with motion sickness.
Primary Outcome
Number of Subjects who developed motion sickness
Interventions
- DRUG Placebos
- DRUG DPI-386 Nasal Gel
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 102 participants |
| Start Date | 2019-06-09 |
| Est. Completion | 2019-06-11 |
| Phase | Phase 3 |
What the finished NCT04184115 record still lists
NCT04184115 is an interventional study that assigns participants to a tested intervention. The registered 102 participants enrollment target is mid-sized for trials with a published cap, below the 772-participant average among 15,282 other Phase 3 trials with a reported enrollment target (87% lower).
The record links to 0 conditions, and to 2 interventions - of which Placebos is the first listed.
NCT04184115 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT04184115 about?
NCT04184115 is a clinical study titled "Nasal Gel for the Prevention and Treatment of Nausea Associated With Motion Sickness". Phase 3 clinical trial is a randomized, double-blind, placebo-controlled study to identify the safety, efficacy and pharmacokinetics of a repeated-dose regimen of DPI 386 nasal gel (intranasal scopolamine gel) for the prevention and treatment of nausea associated with motion sickness.
What is the current status of trial NCT04184115?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 102 participants. The study started on 2019-06-09. Estimated completion is 2019-06-11.
What interventions are being tested in trial NCT04184115?
The interventions under investigation include: Placebos (DRUG), DPI-386 Nasal Gel (DRUG).
Who is sponsoring clinical trial NCT04184115?
This trial is sponsored by Repurposed Therapeutics, which has 9 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT04184115's enrollment target sits among peer trials
102 1676th of 2000 higher than 321 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03704662 · 102 participants · NA
Preoperative Fractionated Radiation Therapy Versus Stereotactic Body Radiation Therapy for Resectable or Borderline Resectable, or Locally Advanced Type A Pancreatic Adenocarcinoma
- NCT04174742 · 102 participants
Self Reported Pain in Women While Undergoing Treatment for Non-metastatic Breast Cancer
- NCT04275362 · 102 participants
Gait Analysis of a Lateral-Pivot Design Total Knee Replacement
- NCT04541082 · 102 participants · Phase 1
Phase I Study of Oral ONC206 in Recurrent and Rare Primary Central Nervous System Neoplasms
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI